RFM
GALT icon

Royal Fund Management’s Galectin Therapeutics GALT Stock Holding History

Royal Fund Management’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-7
Closed – – 293
2020
Q1 		$0 Hold
7
– – ﹤0.01% 625
2019
Q4 		$0 Hold
7
– – ﹤0.01% 650
2019
Q3 		$0 Hold
7
– – ﹤0.01% 605
2019
Q2 		$0 Hold
7
– – ﹤0.01% 579
2019
Q1 		$0 Hold
7
– – ﹤0.01% 610
2018
Q4 		$0 Hold
7
– – ﹤0.01% 605
2018
Q3 		$0 Hold
7
– – ﹤0.01% 564
2018
Q2 		$0 Hold
7
– – ﹤0.01% 581
2018
Q1 		$0 Hold
7
– – ﹤0.01% 585
2017
Q4 		$0 Hold
7
– – ﹤0.01% 655
2017
Q3 		$0 Hold
7
– – ﹤0.01% 478
2017
Q2 		$0 Hold
7
– – ﹤0.01% 463
2017
Q1 		$0 Hold
7
– – ﹤0.01% 435
2016
Q4 		$0 Buy
+7
New +$6 ﹤0.01% 393

Other funds holding GALT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
DADC
D.A. Davidson & Co Great Falls, Montana $16.5B AUM 19.94% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return
CCB
Cutter & Co Brokerage Ballwin, Missouri $423M AUM 15.02% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Royal Fund Management's GALT Position: Q2 2020 in Review

Royal Fund Management sold out of Galectin Therapeutics (GALT) in Q2 2020, closing a stake of 7 shares.

Royal Fund Management first reported a position in GALT in Q4 2016 and held it in 14 quarters. The position peaked at $0 in Q1 2020. 75 funds tracked by Wall St. Rank hold GALT as of Q2 2020.

  • Royal Fund Management reported no remaining Galectin Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Royal Fund Management sold 7 Galectin Therapeutics shares in Q2 2020.
  • Royal Fund Management first reported a position in Galectin Therapeutics in Q4 2016 and held it in 14 quarters.
  • Royal Fund Management's Galectin Therapeutics position peaked at $0 in Q1 2020.
  • 75 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2020.

Based on Royal Fund Management's 13F filing for Q2 2020, filed 6 Aug 2020.